Clinical Trials Logo

Essential Thrombocythemia clinical trials

View clinical trials related to Essential Thrombocythemia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06378437 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of GLB-001 in Patients With Myeloid Malignancies

Start date: April 22, 2024
Phase: Phase 1
Study type: Interventional

Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), lower-risk myelodysplastic syndrome (LR-MDS), higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML). This study consists of 3 parts, dose escalation (Phase 1a), dose exploration (Phase 1b) and dose expansion (Phase 1c). Dose escalation (Phase 1a) and dose exploration (Phase 1b) will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001, administered orally, in study participants with PV/ET, or study participants with MF/LR-MDS/HR-MDS/AML, respectively. Dose expansion (Phase 1c) will be followed to determine the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Approximately 108 study participants may be enrolled in the study.

NCT ID: NCT06361641 Not yet recruiting - Clinical trials for Primary Myelofibrosis

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

PHEMOP
Start date: April 20, 2024
Phase: N/A
Study type: Interventional

Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms